Emerging Designer Drug Monograph

Revision Date: August 11, 2013

Author(s): Elizabeth Schlatter, Barry K. Logan

Drug Name: 25C-NBOMe

Synonyms: 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, monohydrochloride; 2C-C-NBOMe; NBOMe-2C-C; Cimbi-82; Pandora; Dime

Structure:

Formula: C₁₈H₂₂ClNO₃

Molecular Weight: 335.8

Pharmacological Drug Class: 25-C-NBOMe is an hallucinogen. The compound is a partial 5-HT_{2A} agonist (Zuba). Activation of monoamine receptor activity and reuptake inhibition increases synaptic serotonin and norephinepherine resulting in some stimulant effects (See www.caymanchem.com).

Metabolism: The metabolism of 25C-NBOMe has not been outlined. Generally, 2C compounds are metabolized by O-demethylation at position 2 or 5 of the aromatic ring. The compound is deaminated by MAO-A or MAO-B. The deaminated metabolite is then oxidized to the corresponding acid, which is then reduced to the corresponding alcohol. Phase II metabolism incorporates glucoridation or sulfination (Meyer, Maurer).

Blood Concentrations: No blood concentrations have been recorded in 25C-NBOMe literature.

Effects and Toxicity: User reports indicate 25C-NBOMe can be taken nasally, orally, buccally, and sublingually (see www.erowid.org). Reports suggest some stimulant effects including physical and mental stimulation, increased awareness, euphoria, mydriasis, and insomnia. Hallucinogenic effects include spiritual experiences, difficultly focusing, euphoria, and paranoia. According to the DEA toxic effects include seizures, cardiac and respiratory arrest.

Analysis: 25-C-NBOMe is a basic drug that extracts along with amphetamines and chromatographs well through GC-MS after derivatization with trifluoroacetic anhydride (TFAA):chloroform. Dominant ions are observed at m/z 191, 171, and 155 (Zuba). SWGDRUG outlines general GC-MS parameters for 25C-NBOMe analysis and includes sample chromatograms. 25C-NBOMe can also be analysed through LC-MS, NMR, ad FTIR.

References:

- 1. Meyer, M. R., Maurer, H. H. (2010) Metabolism of designer drugs of abuse: an updated review. *Current Drug Metabolism*, 11(5), 468 482. http://www.ncbi.nlm.nih.gov/pubmed/20540700
- 2. Zuba, D., Sekuła, K., Buczek, A. (2013) 25C-NBOMe--new potent hallucinogenic substance identified on the drug market. *Forensic Science International*, 227(1-3), 7 14. http://www.ncbi.nlm.nih.gov/pubmed/22989597

Cayman Chemical https://www.caymanchem.com/pdfs/9001096.pdf

SWGDRUG Monograph http://www.swgdrug.org/Monographs/25C-NBOMe.pdf

2C-NBOMe Erowid http://www.erowid.org/chemicals/nbome/nbome.shtml